Invivyd price target raised to $10 from $5 at H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Invivyd (IVVD) to $10 from $5 and keeps a Buy rating on the shares after the company unveiled the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody for COVID-19 prevention. The firm views the REVOLUTION launch as a “meaningful inflection point” that strengthens Invivyd’s regulatory and commercial narrative.